<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Filgrastim</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Filgrastim">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Filgrastim</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Filgrastim</b>, sold under the brand name <b>Neupogen</b> among others, is a medication used to treat low neutrophil count.<span class="mw-ref" id="cite_ref-AHFS2016_2-0"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause.<span class="mw-ref" id="cite_ref-AHFS2016_2-1"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It may also be used to increase white blood cells for gathering during leukapheresis.<span class="mw-ref" id="cite_ref-AHFS2016_2-2"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is given either by injection into a vein or under the skin.<span class="mw-ref" id="cite_ref-AHFS2016_2-3"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>



<div role="note" class="hatnote navigation-not-searchable">Not to be confused with granulocyte-macrophage colony-stimulating factor or <a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">epoetin alfa</a>.</div>
<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Filgrastim</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Filgrastim.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Filgrastim.jpg" data-file-width="500" data-file-height="500" data-file-type="bitmap" height="184" width="184"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Neupogen, Zarxio, Granix, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>filgrastim-aafi, filgrastim-sndz</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/filgrastim.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/filgrastim.html'" tppabs="https://www.drugs.com/monograph/filgrastim.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a692033.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a692033.html'" tppabs="https://medlineplus.gov/druginfo/meds/a692033.html" class="external text external">a692033</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Filgrastim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Filgrastim'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Filgrastim" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Filgrastim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Filgrastim'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Filgrastim" class="external text external">Filgrastim</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Filgrastim&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Filgrastim&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Filgrastim&SearchType=BasicSearch" class="external text external">Filgrastim</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B3<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_Pregnancy_1-0"><a href="#cite_note-Drugs.com_Pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_Pregnancy_1-1"><a href="#cite_note-Drugs.com_Pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>IV, subQ</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Hematopoietic Agents</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L03AA02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L03AA02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L03AA02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L03AA02" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">Human granulocyte colony stimulating factor</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=121181-53-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=121181-53-1'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=121181-53-1" class="external text external">121181-53-1</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem<span> </span><span style="font-weight:normal"><abbr>SID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505833  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505833'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505833" class="external text external">46505833</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6968  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6968'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6968" class="external text external">6968</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00099'" tppabs="https://www.drugbank.ca/drugs/DB00099" class="external text external">DB00099</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=PVI5M0M1GW  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=PVI5M0M1GW'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=PVI5M0M1GW" class="external text external">PVI5M0M1GW</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D03235  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D03235'" tppabs="https://www.kegg.jp/entry/D03235" class="external text external">D03235</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201567  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201567'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201567" class="external text external">ChEMBL1201567</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.167.401  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.167.401'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.167.401" class="external text external">100.167.401</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>845</sub><span>H</span><sub>1343</sub><span>N</span><sub>223</sub><span>O</span><sub>243</sub><span>S</span><sub>9</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">18<span style="margin-left:.25em;">802</span>.90</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr></tbody></table>


<p>Common side effects include fever, cough, chest pain, joint pain, vomiting, and hair loss.<span class="mw-ref" id="cite_ref-AHFS2016_2-4"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Severe side effects include splenic rupture and allergic reactions.<span class="mw-ref" id="cite_ref-AHFS2016_2-5"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is unclear if use in pregnancy is safe for the baby.<span class="mw-ref" id="cite_ref-AHFS2016_2-6"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Filgrastim is a recombinant-DNA form of the naturally occurring granulocyte colony-stimulating factor (G-CSF).<span class="mw-ref" id="cite_ref-AHFS2016_2-7"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It works by stimulating the body to increase neutrophil production.<span class="mw-ref" id="cite_ref-AHFS2016_2-8"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Filgrastim was approved for medical use in the United States in 1991.<span class="mw-ref" id="cite_ref-AHFS2016_2-9"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_3-0"><a href="#cite_note-WHO21st-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Filgrastim biosimilar medications are available.<span class="mw-ref" id="cite_ref-AHFS2016_2-10"><a href="#cite_note-AHFS2016-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Filgrastim is used to treat neutropenia,<span class="mw-ref" id="cite_ref-pmid18632435_4-0"><a href="#cite_note-pmid18632435-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> stimulating the bone marrow to increase production of neutrophils. Causes of neutropenia include chemotherapy and bone marrow transplantation.</p>

<p>Filgrastim is also used to increase the number of hematopoietic stem cells in the blood before collection by leukapheresis for use in hematopoietic stem cell transplantation.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>The most commonly observed adverse effect is mild bone pain after repeated administration,<span class="mw-ref" id="cite_ref-pmid28423916_5-0"><a href="#cite_note-pmid28423916-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> and local skin reactions at the site of injection.<span class="mw-ref" id="cite_ref-AmgenRx_6-0"><a href="#cite_note-AmgenRx-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Neupogen_label_7-0"><a href="#cite_note-Neupogen_label-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Other observed adverse effects include serious allergic reactions (including a rash over the whole body,<span class="mw-ref" id="cite_ref-pmid19614649_8-0"><a href="#cite_note-pmid19614649-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, and sweating), ruptured spleen (sometimes resulting in death),<span class="mw-ref" id="cite_ref-pmid8450676_9-0"><a href="#cite_note-pmid8450676-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> alveolar hemorrhage, acute respiratory distress syndrome, and hemoptysis.<span class="mw-ref" id="cite_ref-AmgenRx_6-1"><a href="#cite_note-AmgenRx-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Severe sickle cell crises, in some cases resulting in death, have been associated with the use of filgrastim in patients with sickle cell disorders.<span class="mw-ref" id="cite_ref-Neupogen_label_7-1"><a href="#cite_note-Neupogen_label-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Drug interactions between filgrastim and other drugs have not been fully evaluated. Drugs which may potentiate the release of neutrophils‚ such as <a href="Lithium.htm" tppabs="https://ptable.com/wiki/compounds/A/Lithium" title="Lithium">lithium</a>‚ should be used with caution.</p>

<p>Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes; this should be considered when interpreting bone-imaging results.<span class="mw-ref" id="cite_ref-Neupogen_label_7-2"><a href="#cite_note-Neupogen_label-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>Filgrastim has not been studied in pregnant women and its effects on the fetus is unknown. If taking filgrastim while pregnant, it is possible that traces of the drug could be found in the baby's blood. It is not known if the drug can get into human breast milk.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. G-CSF regulates the production of neutrophils within the bone marrow; endogenous G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells.</p>

<p>G-CSF is a colony stimulating factor which has been shown to have minimal direct in vivo or in vitro effects on the production of other haematopoietic cell types. Neupogen (filgrastim) is the name for recombinant methionyl human granulocyte colony stimulating factor (r-metHuG-CSF).<span class="mw-ref" id="cite_ref-Neupogen_label_7-3"><a href="#cite_note-Neupogen_label-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Production">Production</h2></summary>
    
<p>It is produced by recombinant DNA technology. The gene for human granulocyte colony-stimulating factor is inserted into the genetic material of <i>Escherichia coli</i>. The G-CSF then produced by <i>E. coli</i> is different from G-CSF naturally made in humans.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Commercialization">Commercialization</h3></summary>
    
<p>Filgrastim is marketed under several brand names, including:</p>

<table class="wikitable sortable">
<tbody><tr>
<th>Company</th><th>Brand</th></tr>
<tr>
<td>Cadila Pharmaceuticals</td><td><i>Filcad</i></td></tr>
<tr>
<td>Abbott Laboratories</td><td><i>Imumax</i></td></tr>
<tr>
<td>Dr. Reddy's Laboratories</td><td><i>Grafeel</i></td></tr>
<tr>
<td>Intas Biopharmaceuticals</td><td><i>Neukine</i></td></tr>
<tr>
<td>Amgen</td><td><i>Neupogen</i><span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-ap201407_11-0"><a href="#cite_note-ap201407-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></td></tr>
<tr>
<td>Emcure Pharmaceuticals</td><td><i>Emgrast</i></td></tr>
<tr>
<td><span class="new">Reliance Life Sciences</span></td><td><i>Religrast</i></td></tr>
<tr>
<td>Novartis/Sandoz</td><td><i>Zarzio</i><span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> and <i>Zarxio</i><span class="mw-ref" id="cite_ref-FDA_Zarxio_2015_14-0"><a href="#cite_note-FDA_Zarxio_2015-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></td></tr>
<tr>
<td>Biocon</td><td><i>Nufil</i></td></tr>
<tr>
<td>Pfizer</td><td><i>Nivestim</i><span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> and <i>Nivestym</i><span class="mw-ref" id="cite_ref-Nivestym_PR_17-0"><a href="#cite_note-Nivestym_PR-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></td></tr>

</tbody></table>

<p>Apricus Biosciences is currently developing and testing a product under the brand name <i>Nupen</i> which can deliver filgrastim through the skin to improve post-chemotherapy recovery of neutrophil counts.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>In 2015, Sandoz's filgrastim-sndz (trade name Zarxio), obtained the approval of the U.S. Food and Drug Administration (FDA) as a biosimilar.<span class="mw-ref" id="cite_ref-FDA_Zarxio_2015_14-1"><a href="#cite_note-FDA_Zarxio_2015-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-NYT_Zarxio_19-0"><a href="#cite_note-NYT_Zarxio-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> This was the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), as part of the Affordable Care Act.<span class="mw-ref" id="cite_ref-FDA_Zarxio_2015_14-2"><a href="#cite_note-FDA_Zarxio_2015-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Zarxio was approved as a biosimilar, not as an interchangeable product, the FDA notes. And under the BPCI Act, only a biologic that has been approved as an "interchangeable" may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The FDA said its approval of Zarxio is based on review of evidence that included structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Zarxio" title="Zarxio" class="mw-redirect">Zarxio</a> is biosimilar to Neupogen.<span class="mw-ref" id="cite_ref-NYT_Zarxio_19-1"><a href="#cite_note-NYT_Zarxio-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<style data-mw-deduplicate="TemplateStyles:r960796168">.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}</style><blockquote class="templatequote"><p>Zarxio is approved for the same indications as Neupogen, and can be prescribed by a health care professional for: patients with cancer receiving myelosuppressive chemotherapy; patients with acute myeloid leukemia receiving induction or consolidation chemotherapy; patients with cancer undergoing bone marrow transplantation; patients undergoing autologous peripheral blood progenitor cell collection and therapy; and patients with severe chronic neutropenia.</p><div class="templatequotecite">—<span> </span><cite>FDA, March 6, 2015</cite></div></blockquote>

<p>In 2018, filgrastim-aafi (trade name Nivestym) was approved for use in the United States.<span class="mw-ref" id="cite_ref-Nivestym_PR_17-1"><a href="#cite_note-Nivestym_PR-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>Neukine is an Indian biosimlar filgrastim and approved for the same indications as of Neupogen. Neukine is manufactured and marketed by Intas Pharmaceuticals Limited at Ahmedabad, India.</p>

<p>In September 2008, Ratiograstim, Tevagrastim, Biograstim, and Filgrastim ratiopharm were approved for use in the European Union.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Filgrastim ratiopharm was withdrawn in July 2011 and Biograstim was withdrawn in December 2016.</p>

<p>In February 2009, Filgrastim Hexal and Zarzio were approved for use in the European Union.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>

<p>In June 2010, Nivestim was approved for use in the European Union.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>

<p>In October 2013, Grastofil was approved for use in the European Union.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>

<p>In September 2014, Accofil was approved for use in the European Union.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cost">Cost</h3></summary>
    
<p>Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia depended upon the clinical situation and the financial model used to pay for treatment.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span>  The longer-acting <a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">pegfilgrastim</a> may in some cases be more cost-effective.<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span>  The introduction of biosimilars into the market resulted in a price reduction for the original, patent-protected product and increased use.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Granulocyte macrophage colony-stimulating factor, as a drug, (<a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a>) ( Leukine)</li>
<li>Immune system</li>
<li>Lipegfilgrastim (Lonquex), a PEGylated form of filgrastim</li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a> (Neulasta), a PEGylated form of filgrastim</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_Pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_Pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/filgrastim.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/filgrastim.html'" tppabs="https://www.drugs.com/pregnancy/filgrastim.html" class="external text external">"Filgrastim Use During Pregnancy"</a>. <i>Drugs.com</i>. 13 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">17 December</span> 2019</span>.</cite></span></li><li id="cite_note-AHFS2016-2"> <span id="mw-reference-text-cite_note-AHFS2016-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/filgrastim.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/filgrastim.html'" tppabs="https://www.drugs.com/monograph/filgrastim.html" class="external text external">"Filgrastim"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20170510112413/https://www.drugs.com/monograph/filgrastim.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170510112413/https://www.drugs.com/monograph/filgrastim.html'" tppabs="https://web.archive.org/web/20170510112413/https://www.drugs.com/monograph/filgrastim.html" class="external text external">Archived</a> from the original on 10 May 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-WHO21st-3"> <span id="mw-reference-text-cite_note-WHO21st-3" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-pmid18632435-4"> <span id="mw-reference-text-cite_note-pmid18632435-4" class="mw-reference-text"><cite id="CITEREFCrawfordGlaspyStollerTomita2005" class="citation journal cs1">Crawford, J.; Glaspy, J. A.; Stoller, R. G.; Tomita, D. K.; Vincent, M. E.; McGuire, B. W.; Ozer, H. (2005). "Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia". <i>Supportive Cancer Therapy</i>. <b>3</b> (1): 36–46. doi:<a href="javascript:if(confirm('https://doi.org/10.3816%2FSCT.2005.n.023  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3816%2FSCT.2005.n.023'" tppabs="https://doi.org/10.3816%2FSCT.2005.n.023" class="external text external">10.3816/SCT.2005.n.023</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18632435  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18632435'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18632435" class="external text external">18632435</a>.</cite></span></li><li id="cite_note-pmid28423916-5"> <span id="mw-reference-text-cite_note-pmid28423916-5" class="mw-reference-text"><cite id="CITEREFMoorePellegrino2017" class="citation journal cs1">Moore DC, Pellegrino AE (September 2017). "Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management". <i>Ann Pharmacother</i>. <b>51</b> (9): 797–803. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1060028017706373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1060028017706373'" tppabs="https://doi.org/10.1177%2F1060028017706373" class="external text external">10.1177/1060028017706373</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28423916  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28423916'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28423916" class="external text external">28423916</a>.</cite></span></li><li id="cite_note-AmgenRx-6"> <span id="mw-reference-text-cite_note-AmgenRx-6" class="mw-reference-text">Neupogen <cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medicines.org.uk/emc/medicine/27485  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicines.org.uk/emc/medicine/27485'" tppabs="http://www.medicines.org.uk/emc/medicine/27485" class="external text external">"Neupogen: Patient Information Leaflet"</a>. Amgen. <a href="javascript:if(confirm('https://web.archive.org/web/20131110185048/http://www.medicines.org.uk/emc/medicine/27485  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131110185048/http://www.medicines.org.uk/emc/medicine/27485'" tppabs="https://web.archive.org/web/20131110185048/http://www.medicines.org.uk/emc/medicine/27485" class="external text external">Archived</a> from the original on 10 November 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2013</span>.</cite></span></li><li id="cite_note-Neupogen_label-7"> <span id="mw-reference-text-cite_note-Neupogen_label-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193" class="external text external">"Neupogen- filgrastim injection, solution"</a>. <i>DailyMed</i>. 15 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-pmid19614649-8"> <span id="mw-reference-text-cite_note-pmid19614649-8" class="mw-reference-text"><cite id="CITEREFScottSilbersteinFlatleyArdeshna2009" class="citation journal cs1">Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S (September 2009). "Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption". <i>Br. J. Dermatol</i>. <b>161</b> (3): 717–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2133.2009.09371.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2133.2009.09371.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2133.2009.09371.x" class="external text external">10.1111/j.1365-2133.2009.09371.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19614649  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19614649'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19614649" class="external text external">19614649</a>.</cite></span></li><li id="cite_note-pmid8450676-9"> <span id="mw-reference-text-cite_note-pmid8450676-9" class="mw-reference-text"><cite id="CITEREFZimmerBerdelLudwigNotter1993" class="citation journal cs1">Zimmer BM, Berdel WE, Ludwig WD, Notter M, Reufi B, Thiel E (March 1993). "Fatal spleen rupture during induction chemotherapy with rh GM-CSF priming for acute monocytic leukemia. Clinical case report and in vitro studies". <i>Leuk. Res</i>. <b>17</b> (3): 277–83. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0145-2126%2893%2990012-a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0145-2126%2893%2990012-a'" tppabs="https://doi.org/10.1016%2F0145-2126%2893%2990012-a" class="external text external">10.1016/0145-2126(93)90012-a</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8450676  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8450676'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8450676" class="external text external">8450676</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103353  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103353'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103353" class="external text external">"Neupogen"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-ap201407-11"> <span id="mw-reference-text-cite_note-ap201407-11" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.dddmag.com/news/2014/07/fda-reviews-what-could-be-first-biosimilar?et_cid=4065898&et_rid=280926499&type=cta  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.dddmag.com/news/2014/07/fda-reviews-what-could-be-first-biosimilar?et_cid=4065898&et_rid=280926499&type=cta'" tppabs="http://www.dddmag.com/news/2014/07/fda-reviews-what-could-be-first-biosimilar?et_cid=4065898&et_rid=280926499&type=cta" class="external text external">"FDA Reviews What Could Be First Biosimilar"</a>. <i>Discov. Dev. Mag</i>. Rockaway, New Jersey, United States. Associated Press. 25 July 2014. <a href="javascript:if(confirm('https://web.archive.org/web/20140729024124/http://www.dddmag.com/news/2014/07/fda-reviews-what-could-be-first-biosimilar?et_cid=4065898&et_rid=280926499&type=cta  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140729024124/http://www.dddmag.com/news/2014/07/fda-reviews-what-could-be-first-biosimilar?et_cid=4065898&et_rid=280926499&type=cta'" tppabs="https://web.archive.org/web/20140729024124/http://www.dddmag.com/news/2014/07/fda-reviews-what-could-be-first-biosimilar?et_cid=4065898&et_rid=280926499&type=cta" class="external text external">Archived</a> from the original on 29 July 2014.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio" class="external text external">"Zarzio EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/6672/smpc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/6672/smpc'" tppabs="https://www.medicines.org.uk/emc/product/6672/smpc" class="external text external">"Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC)"</a>. <i>(emc)</i>. 4 July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-FDA_Zarxio_2015-14"> <span id="mw-reference-text-cite_note-FDA_Zarxio_2015-14" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20151211053044/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151211053044/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm'" tppabs="https://web.archive.org/web/20151211053044/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm" class="external text external">"FDA approves first biosimilar product Zarxio"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 6 March 2015. Archived from <a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm" class="external text external">the original</a> on 11 December 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">23 November</span> 2015</span>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim" class="external text external">"Nivestim EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/575/smpc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/575/smpc'" tppabs="https://www.medicines.org.uk/emc/product/575/smpc" class="external text external">"Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC)"</a>. <i>(emc)</i>. 18 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-Nivestym_PR-17"> <span id="mw-reference-text-cite_note-Nivestym_PR-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm" class="external text external">"Drug Approval Package: Nivestym (filgrastim-aafi)"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 21 February 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191220184614/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191220184614/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm'" tppabs="https://web.archive.org/web/20191220184614/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761080Orig1s000TOC.cfm" class="external text external">Archived</a> from the original on 20 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm" class="external text external">"Zarxio (filgrastim-sndz)"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 20 April 2015. <a href="javascript:if(confirm('https://web.archive.org/web/20191220184811/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191220184811/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm'" tppabs="https://web.archive.org/web/20191220184811/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm" class="external text external">Archived</a> from the original on 20 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2019</span>.</cite></span></li><li id="cite_note-NYT_Zarxio-19"> <span id="mw-reference-text-cite_note-NYT_Zarxio-19" class="mw-reference-text"><cite id="CITEREFTavernisePollack2015" class="citation news cs1">Tavernise, Sabrina; Pollack, Andrew (6 March 2015). <a href="javascript:if(confirm('https://www.nytimes.com/2015/03/07/health/fda-approves-zarxio-first-biosimilar-drug.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2015/03/07/health/fda-approves-zarxio-first-biosimilar-drug.html'" tppabs="https://www.nytimes.com/2015/03/07/health/fda-approves-zarxio-first-biosimilar-drug.html" class="external text external">"F.D.A. Approves Zarxio, Its First Biosimilar Drug"</a>. <i>The New York Times</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20151023143537/http://www.nytimes.com/2015/03/07/health/fda-approves-zarxio-first-biosimilar-drug.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151023143537/http://www.nytimes.com/2015/03/07/health/fda-approves-zarxio-first-biosimilar-drug.html'" tppabs="https://web.archive.org/web/20151023143537/http://www.nytimes.com/2015/03/07/health/fda-approves-zarxio-first-biosimilar-drug.html" class="external text external">Archived</a> from the original on 23 October 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">23 November</span> 2015</span>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/ratiograstim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/ratiograstim'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/ratiograstim" class="external text external">"Ratiograstim EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/tevagrastim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/tevagrastim'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/tevagrastim" class="external text external">"Tevagrastim EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/Biograstim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/Biograstim'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/Biograstim" class="external text external">"Biograstim EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-ratiopharm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-ratiopharm'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-ratiopharm" class="external text external">"Filgrastim ratiopharm EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal" class="external text external">"Filgrastim Hexal EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/zarzio" class="external text external">"Zarzio EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim" class="external text external">"Nivestim EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/grastofil  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/grastofil'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/grastofil" class="external text external">"Grastofil EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/accofil  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/accofil'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/accofil" class="external text external">"Accofil EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFNeymark1998" class="citation book cs1">Neymark, Niels (1998). <i>Assessing the Economic Value of Anticancer Therapies</i>. Berlin, Heidelberg: Springer Berlin Heidelberg. pp.<span>&nbsp;</span>215–219. ISBN<span>&nbsp;</span><bdi>978-3-642-72123-6</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/851760173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/851760173'" tppabs="https://www.worldcat.org/oclc/851760173" class="external text external">851760173</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFEllery2012" class="citation book cs1">Ellery, Tony (2012). <i>Pharmaceutical lifecycle management<span>&nbsp;</span>: making the most of each and every brand</i>. Hansen, Neal. Hoboken, N.J.: John Wiley &amp; Sons. p.<span>&nbsp;</span>214. ISBN<span>&nbsp;</span><bdi>978-1-118-26679-3</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/797824835  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/797824835'" tppabs="https://www.worldcat.org/oclc/797824835" class="external text external">797824835</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite id="CITEREFCornes" class="citation book cs1">Cornes, Paul. <a href="javascript:if(confirm('https://www.worldcat.org/oclc/1064690227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/1064690227'" tppabs="https://www.worldcat.org/oclc/1064690227" class="external text external"><i>Biosimilars</i></a>. Bennett, David. Abingdon. p.<span>&nbsp;</span>54. ISBN<span>&nbsp;</span><bdi>978-1-910797-67-9</bdi>. OCLC<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/oclc/1064690227  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/oclc/1064690227'" tppabs="https://www.worldcat.org/oclc/1064690227" class="external text external">1064690227</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFSantosovan_BoxtelEdwards2001" class="citation book cs1">Santoso B, van Boxtel CJ, Edwards RI, eds. (2001). <i>Drug benefits and risks: international textbook of clinical pharmacology</i>. New York: Wiley. ISBN<span>&nbsp;</span><bdi>0-471-89927-5</bdi>.</cite></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/filgrastim  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/filgrastim'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/filgrastim" class="external text external">"Filgrastim"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Immunostimulants_(L03)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunostimulants_(L03)" style="font-size:114%;margin:0 4em">Immunostimulants (L03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Endogenous</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Cytokines</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Colony-stimulating factors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>G-CSF
<ul><li><a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a> / Lipegfilgrastim / <a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li>Lenograstim</li>
<li><i>Eflapegrastim</i></li></ul></li>
<li>GM-CSF
<ul><li>Molgramostim</li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul></li>
<li>SCF
<ul><li>Ancestim</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interferons</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>alpha</i>:
<ul><li>Albinterferon</li>
<li>Interferon alfa natural</li>
<li><span class="new">Interferon alfa 2a</span> / Peginterferon alfa-2a</li>
<li>Interferon alfa 2b / Peginterferon alfa-2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li></ul></li>
<li><i>beta</i>:
<ul><li>Interferon beta natural</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li></ul></li>
<li>Interferon gamma</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interleukins</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Aldesleukin</a></li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other protein / peptide</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Immunocyanin</li>
<li><a href="Adenosine_deaminase.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegademase" title="Pegademase" class="mw-redirect">Pegademase</a></li>
<li>Prolactin</li>
<li>Tasonermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Female sex steroids</li>
<li><a href="Histamine_dihydrochloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine_dihydrochloride" title="Histamine dihydrochloride">Histamine dihydrochloride</a></li>
<li>Poly ICLC</li>
<li><a href="Vitamin_D.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_D" title="Vitamin D">Vitamin D</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Exogenous</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>beta-glucan
<ul><li>Lentinan</li></ul></li>
<li>heterocyclic compound
<ul><li>Plerixafor</li></ul></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">hydroxyquinoline</a>
<ul><li>Roquinimex</li></ul></li>
<li>Mifamurtide</li>
<li>oligopeptides
<ul><li><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li>Thymopentin</li>
<li>Thymosin α1</li>
<li>Thymulin</li></ul></li>
<li>polyribonucleotide
<ul><li>Polyinosinic:polycytidylic acid</li></ul></li>
<li><a href="Thiazolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidine" title="Thiazolidine">thiazolidine</a>
<ul><li><a href="Pidotimod.htm" tppabs="https://ptable.com/wiki/compounds/A/Pidotimod" title="Pidotimod">Pidotimod</a></li></ul></li>
<li>vaccines
<ul><li>Bacillus Calmette–Guérin</li>
<li>Melanoma vaccine</li>
<li>Sipuleucel-T</li></ul></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Cytokine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cytokine_receptor_modulators" style="font-size:114%;margin:0 4em">Cytokine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CSF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Erythropoietin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">ARA-290</span></li>
<li><span class="new">Asialo erythropoietin</span></li>
<li><span class="new">Carbamylated erythropoietin</span></li>
<li><span class="new">CNTO-530</span></li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li><a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">Epoetin alfa</a></li>
<li>Epoetin beta</li>
<li><span class="new">Epoetin delta</span></li>
<li><span class="new">Epoetin epsilon</span></li>
<li><span class="new">Epoetin gamma</span></li>
<li><span class="new">Epoetin kappa</span></li>
<li><span class="new">Epoetin omega</span></li>
<li><span class="new">Epoetin theta</span></li>
<li>Epoetin zeta</li>
<li>Erythropoietin (EPO)</li>
<li><span class="new">Erythropoietin-Fc</span></li>
<li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li>
<li>Peginesatide</li>
<li><span class="new">Pegol sihematide (EPO-018B)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">G-CSF (CSF3)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a></li>
<li>Granulocyte colony-stimulating factor</li>
<li>Lenograstim</li>
<li><span class="new">Leridistim</span></li>
<li>Lipegfilgrastim</li>
<li><span class="new">Nartograstim</span></li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li><span class="new">Pegnartograstim</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GM-CSF (CSF2)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ecogramostim</span></li>
<li>Granulocyte macrophage colony-stimulating factor</li>
<li><span class="new">Milodistim</span></li>
<li>Molgramostim</li>
<li><span class="new">Regramostim</span></li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul>

<ul><li><i>Antibodies:</i> Mavrilimumab</li>
<li>Namilumab</li>
<li>Otilimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">M-CSF (CSF1)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cilmostim</span></li>
<li>Interleukin-34</li>
<li><span class="new">Lanimostim</span></li>
<li>Macrophage colony-stimulating factor</li>
<li><span class="new">Mirimostim</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Thrombopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Eltrombopag</li>
<li><span class="new">Pegacaristim</span></li>
<li>Promegapoietin</li>
<li>Romiplostim</li>
<li>Thrombopoietin (THPO, MGDF)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNAR (α/β, I)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albinterferon</li>
<li>Interferon alpha (interferon alfa, IFN-α)</li>
<li>Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)</li>
<li><span class="new">Interferon alfa 2a</span></li>
<li>Interferon alfa 2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li>
<li>Interferon beta (IFN-β) (IFNB1, <span class="new">IFNB3</span>)</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li>
<li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li>
<li>Interferon omega (IFN-ω, IFNW1)</li>
<li>Peginterferon alfa-2a</li>
<li>Peginterferon alfa-2b</li></ul>

<ul><li><i>Antibodies:</i> Anifrolumab</li>
<li>Faralimomab</li>
<li><span class="new">MEDI-545</span></li>
<li>Rontalizumab</li>
<li>Sifalimumab</li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">Bifarcept</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNGR (γ, II)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interferon gamma (IFN-γ)</li>
<li><span class="new">Interferon gamma 1b</span></li></ul>

<ul><li><i>Antibodies:</i> Emapalumab</li>
<li>Fontolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNLR (λ, III)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See IL-28R (IFNLR) here instead.</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TNF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Baricitinib</li>
<li>Filgotinib</li>
<li>Momelotinib</li>
<li>Oclacitinib</li>
<li>Ruxolitinib</li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li>Upadacitinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li>Atiprimod</li>
<li><span class="new">AZD-1480</span></li>
<li>Baricitinib</li>
<li><span class="new">CHZ868</span></li>
<li>Cucurbitacin I (elatericin B, JSI-124)</li>
<li>CYT387</li>
<li>Lestaurtinib</li>
<li><span class="new">NSC-7908</span></li>
<li><span class="new">NSC-33994</span></li>
<li>Pacritinib</li>
<li>Ruxolitinib</li>
<li><span class="new">SD-1008</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li><span class="new">Cercosporamide</span></li>
<li>Decernotinib (VX-509)</li>
<li><span class="new">TCS-21311</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li><span class="new">WHI-P 154</span></li>
<li><span class="new">ZM-39923</span></li>
<li><span class="new">ZM-449829</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional cytokines:</i> Cardiotrophin 1 (CT-1)</li>
<li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li>
<li>Leukemia/leukocyte inhibitory factor (LIF)</li>
<li>Oncostatin M (OSM)</li>
<li>Thymic stromal lymphopoietin (TSLP)</li></ul>

<ul><li><i>Additional cytokine receptor modulators:</i> <span class="new">Emfilermin</span></li>
<li>Lestaurtinib</li>
<li>Midostaurin</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Growth factor receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>













<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-09" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Filgrastim&oldid=972042672  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Filgrastim&oldid=972042672'" tppabs="https://en.wikipedia.org/wiki/?title=Filgrastim&oldid=972042672">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>